Original Article |
| ![](/img/icon_oaccess.png) |
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease
Faris Zvizdic, Edin Begic, Aida Mujakovic, Enisa Hodzic, Besim Prnjavorac, Omer Bedak, Faruk Custovic, Haris Bradaric, Azra Durak-Nalbantic. Abstract | | | | Introduction: The most appropriate choice of pharmacological treatment of heart rhythm disorders occurring in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular comorbidity is often a topic of debate between pulmonologists and cardiologists in clinical practice, although numerous studies and clinical trials have demonstrated evidence to support the use of selective beta-blockers (BBs) in these patients. Aim: To examine the difference in the number of exacerbations in patients treated with a combination of verapamil and digoxin or BB alone in patients with different COPD stages. Patients and methods: The study included 68 patients (n = 68) diagnosed with COPD who were followed-up during a 12-month period, and the number of exacerbations were analyzed. The patients were divided into two groups according to the stage of COPD: GOLD II (moderate), and GOLD III (severe), and in each group a subdivision was established in relation to the use of either a combination of verapamil and digoxin or the use of BBs alone in pharmacological treatment. The inclusion criteria for patients were defined as following: a) established diagnosis of COPD according to present or deteriorated relevant clinical symptoms and signs, b) the ejection fraction (EF) of a left ventricle (LV) >35%, and c) spirometric cut-points classified as GOLD II (FEV1 / FVC
Key words: Chronic Obstructive Pulmonary Diseases, Safety, Treatment, Beta blockers.
|
|
|
|